Drug Profile

TCM 800B

Latest Information Update: 30 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator TCM Biotech International
Developer Industrial Technology Research Institute; TCM Biotech International
Class
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

30 Aug 2023 NDR #29: Development has been discontinued as there is no development from 4 years and drug is no longer visible on the company pipeline. Introduction updated. Dev line forwarded from NDR to discontinued, HE added. Introduction updated.
30 Aug 2023 Discontinued - Preclinical for Hepatitis B in Taiwan (unspecified route) (TCM Biotech pipeline, August 2023)
28 Feb 2019 No recent reports of development identified for preclinical development in Hepatitis-B in Taiwan

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com